Skip to main content
Premium Trial:

Request an Annual Quote

Covance Buys Caprion Proteomics Equity Stake

NEW YORK (GenomeWeb News) – Princeton, NJ-based drug development services company Covance announced yesterday that it has purchased an undisclosed minority stake in the proteomics-based pharmaceutical services company Caprion Proteomics.
Under the agreement, Covance will use Caprion as its exclusive proteomic discovery provider and will act as the exclusive contract research organization distributor for Caprion’s proteomic biomarker services.
The move is aimed at augmenting the biomarker services Covance offers its pharmaceutical and biotechnology drug development customers. The biomarker discovery, validation, and deployment efforts are aimed at improving drug discovery, approval, and monitoring — spanning proof-of-concept studies to clinical trials and post-marketing surveillance.
Covance also announced that it intends to establish a Biomarker Center of Excellence, which will focus on biomarker testing and validation, at its Greenfield, Ind., campus. Former Pfizer scientist Thomas Turi, who was recently hired as vice president of biomarkers for Covance, will lead the new center.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.